GC Biopharma Corp. (KRX: 006280)

GC Biopharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	44,867	49,706	105,366	186,060	232,288	98,462
Short-Term Investments	-	-0	-0	-	-	-0
Trading Asset Securities	1,800	5,800	6,940	16,875	23,210	43,069
Cash & Short-Term Investments	46,667	55,506	112,306	202,935	255,498	141,531
Cash Growth	-33.62%	-50.58%	-44.66%	-20.57%	80.52%	32.59%
Accounts Receivable	466,460	436,957	394,155	413,817	402,088	388,325
Other Receivables	8,670	11,976	13,778	9,624	20,598	16,840
Receivables	480,030	450,933	409,433	423,987	422,736	405,165
Inventory	671,232	516,245	442,408	454,976	437,071	406,557
Prepaid Expenses	6,073	4,147	4,157	3,275	9,513	3,343
Other Current Assets	19,221	12,316	12,133	5,346	7,223	5,185
Total Current Assets	1,223,224	1,039,148	980,437	1,090,519	1,132,042	961,780
Property, Plant & Equipment	932,948	952,703	930,822	899,847	751,099	718,730
Long-Term Investments	223,695	206,646	216,273	110,962	92,030	121,500
Goodwill	-	142,475	142,475	142,475	10,065	10,065
Other Intangible Assets	329,349	86,166	76,735	57,240	31,797	27,233
Long-Term Deferred Tax Assets	37,311	35,185	27,839	19,832	20,686	22,450
Long-Term Deferred Charges	-	109,240	92,353	77,691	67,702	65,719
Other Long-Term Assets	48,543	68,972	53,824	63,299	45,700	31,772
Total Assets	2,795,349	2,643,314	2,525,537	2,462,145	2,151,400	1,959,300
Accounts Payable	144,515	143,816	121,270	119,541	134,785	139,270
Accrued Expenses	54,798	34,000	102,066	85,781	82,684	71,367
Short-Term Debt	419,298	315,447	182,000	104,836	203,200	41,133
Current Portion of Long-Term Debt	16,647	202,813	5,416	120,539	91,175	93,164
Current Portion of Leases	14,381	14,336	11,580	9,887	7,505	6,067
Current Income Taxes Payable	8,422	2,041	17,158	28,338	11,663	4,168
Current Unearned Revenue	1,841	1,629	7,084	7,730	582	148
Other Current Liabilities	131,237	154,835	94,165	76,231	57,810	46,106
Total Current Liabilities	791,138	868,917	540,738	552,883	589,403	401,423
Long-Term Debt	339,440	84,891	278,797	280,343	194,160	272,086
Long-Term Leases	103,012	106,536	97,751	90,969	70,392	70,731
Long-Term Unearned Revenue	7,421	7,500	14,049	16,296	5,606	5,907
Long-Term Deferred Tax Liabilities	2,262	2,213	1,358	1,869	1,876	1,591
Other Long-Term Liabilities	27,417	32,038	25,031	18,531	14,946	8,235
Total Liabilities	1,271,787	1,103,451	958,895	962,388	882,094	775,223
Common Stock	58,433	58,433	58,433	58,433	58,433	58,433
Additional Paid-In Capital	394,498	393,605	393,531	385,821	337,016	335,960
Retained Earnings	856,883	872,989	903,467	867,353	757,278	679,527
Treasury Stock	-35,702	-35,702	-35,702	-35,702	-35,702	-35,702
Comprehensive Income & Other	15,179	10,912	8,394	-1,134	1,498	10,514
Total Common Equity	1,289,291	1,300,236	1,328,122	1,274,771	1,118,524	1,048,732
Minority Interest	234,272	239,627	238,520	224,987	150,782	135,345
Shareholders' Equity	1,523,563	1,539,863	1,566,642	1,499,757	1,269,306	1,184,077
Total Liabilities & Equity	2,795,349	2,643,314	2,525,537	2,462,145	2,151,400	1,959,300
Total Debt	892,779	724,022	575,543	606,574	566,432	483,181
Net Cash (Debt)	-846,112	-668,516	-463,238	-403,639	-310,934	-341,650
Net Cash Per Share	-74134.63	-58574.05	-40587.96	-79874.09	-27243.38	-29934.66
Filing Date Shares Outstanding	11.41	11.41	11.41	11.41	11.41	11.41
Total Common Shares Outstanding	11.41	11.41	11.41	11.41	11.41	11.41
Working Capital	432,086	170,231	439,698	537,637	542,639	560,357
Book Value Per Share	112965.13	113924.12	116367.45	111692.86	98002.82	91887.77
Tangible Book Value	959,942	1,071,595	1,108,912	1,075,056	1,076,662	1,011,433
Tangible Book Value Per Share	84108.21	93891.05	97160.69	94194.24	94334.96	88619.76
Land	-	17,346	17,383	18,025	17,976	19,192
Buildings	-	695,794	638,353	572,756	508,734	465,341
Machinery	-	407,055	369,503	333,326	310,115	285,053
Construction In Progress	-	59,224	103,334	150,176	85,095	103,132

Source: S&P Capital IQ. Standard template. Financial Sources.